(Q33256995)

24 July 2017

Impact of microarray data quality on genomic data submissions to the FDA. (English)

1 reference

24 July 2017

0 references

Felix W Frueh

1

1 reference

24 July 2017

1 September 2006

1 reference

24 July 2017

1 reference

24 July 2017

24

1 reference

24 July 2017

1105-1107

1 reference

24 July 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt0906-1105

24 July 2017

0 references

cites work

The Sequence of the Human Genome

1 reference

https://api.crossref.org/works/10.1038%2FNBT0906-1105

QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0906-1105

Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0906-1105

Initial sequencing and analysis of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0906-1105

inferred from DOI database lookup

7 January 2021

based on heuristic

Pharmacogenomic-guided drug development: regulatory perspective

1 reference

https://api.crossref.org/works/10.1038%2FNBT0906-1105

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NBT0906-1105

1 reference

release_wgp75r7fyvh3lnwbifeaqzxksq

24 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wgp75r7fyvh3lnwbifeaqzxksq

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16964222

1 reference

PubMed ID

16964222